drugset / Trial / NCT01376089

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

NCT01376089

Phase 4 Completed 304 enrolled GE Healthcare i3 Statprobe · collab
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of the abdomen/pelvis.

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Iodixanol Diagnostic / imaging agent 320 mg/ml Intravenous
Comparator Iopamidol Diagnostic / imaging agent 370 mg/ml Intravenous

Indications

No indication recorded.